R11, a novel cell-permeable peptide, as an intravesical delivery vehicle

BJU International

Volumn 108, Issue 10, 2011, Pages 1666-1671

  Hsieh, Jer Tsong ^a   Zhou, Jian ^a   Gore, Crystal ^a   Zimmern, Philippe ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

bladder; cell permeable peptide; intravesical delivery; polyarginine peptide

Indexed keywords

DRUG VEHICLE; FLUORESCEIN ISOTHIOCYANATE; R11; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CELL TRANSPORT; CLINICAL EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERMETHOD COMPARISON; LAMINA PROPRIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ADMINISTRATION, INTRAVESICAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; MICE; MICE, NUDE; OLIGOPEPTIDES; PEPTIDES; TUMOR CELLS, CULTURED; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 80255137133     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10185.x     Document Type: Article

References (24)

1. Sugimoto K, Nishida M, Otsuka M, et al,. Novel real-time sensors to quantitatively assess in vivo inositol 1, 4, 5-triphosphate production in intact cells. Chem Biol 2004; 11: 475-85 (Pubitemid 38503582)
2. Pugliese A, Vidotto V, Beltramo T, Petrini S, Torre D,. A review of HIV-1 Tat protein biological effects. Cell Biochem Funct 2005; 23: 223-7 (Pubitemid 40992780)
3. Fawell S, Seery J, Daikh Y, et al,. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A 1994; 84: 664-8 (Pubitemid 24041462)
4. Vivès E, Brodin P, Lebleu B,. A truncated HIV-I Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the ceu nucleus. J Biol Chem 1991; 202: 16010-7
5. Derossi D, Chassaing G, Prochiantz A,. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 1998; 8: 84-7 (Pubitemid 28056816)
6. Elliott G, O'Hare P,. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88: 223-33 (Pubitemid 28015871)
7. Pooga M, Hällbrink M, Zorko M, Langel U,. Cell penetration by transportan. FASEB J 1998; 12: 67-77 (Pubitemid 28060272)
8. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB,. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A 2000; 97: 13003-8
9. Futaki S,. Oligoarginine vectors for intracellular delivery: design and cellular-uptake mechanisms. Biopolymers 2006; 84: 241-9
10. Noguchi H, Matsushita M, Okitsu T, et al,. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med 2004; 10: 305-9 (Pubitemid 38667623)
11. Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, Katsuoka Y,. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol 2003; 169: 2372-7 (Pubitemid 36576803)
12. Camps JL, Chang SM, Hsu TC, et al,. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci U S A 1990; 87: 75-9
13. Galustian C, Foulds S, Dye JF, Guillou PJ,. Swainsonine, a glycosylation inhibitor, enhances both lymphocyte efficacy and tumour susceptibility in LAK and NK cytotoxicity. Immunopharmacology 1994; 27: 165-72 (Pubitemid 24073727)
14. Muto S, Sakuma K, Taniguchi A, Matsumoto K,. Human mannose-binding lectin preferentially binds to human colon adenocarcinoma cell lines expressing high amount of Lewis A and Lewis B antigens. Biol Pharm Bull 1994; 22: 347-52 (Pubitemid 29219975)
15. Ziegler A, Nervi P, Dürrenberger M, Seelig J,. The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence. Biochemistry 2005; 44: 138-48 (Pubitemid 40095715)
16. Xie J, Yu BF, Xu J, et al,. Protein transduction domain of membrane penetrating peptide can efficiently deliver DNA and protein into mouse liver for gene therapy. Hepatobiliary Pancreat Dis Int 2005; 4: 90-3 (Pubitemid 40347522)
17. Wadia JS, Dowdy SF,. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005; 57: 579-96 (Pubitemid 40255562)
18. Turner JJ, Ivanova GD, Verbeure B, et al,. Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res 2005; 33: 6837-49 (Pubitemid 43000315)
19. Torchilin VP,. Fluorescence microscopy to follow the targeting of liposomes and micelles to cells and their intracellular fate. Adv Drug Deliv Rev 2005; 57: 95-109 (Pubitemid 39424066)
20. Saar K, Lindgren M, Hansen M, et al,. Cell-penetrating peptides: a comparative membrane toxicity study. Anal Biochem 2005; 345: 55-65 (Pubitemid 41558194)
21. El-Andaloussi S, Holm T, Langel U,. Cell-penetrating peptides: mechanisms and applications. Curr Pharm Des 2005; 11: 3597-611 (Pubitemid 41630987)
22. Deshayes S, Morris MC, Divita G, Heitz F,. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 2005; 62: 1839-49 (Pubitemid 41188523)
23. Mai JC, Shen H, Watkins SC, Cheng T, Robbins PD,. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J Biol Chem 2002; 277: 30208-18
24. Zhou J, Fan J, Hsieh JT,. Inhibition of mitogens-elicited signal transduction and growth in prostate cancer with a small peptide derived from the functional domain of DOC-2/DAB2 delivered by a unique vehicle. Cancer Res 2006; 66: 8954-8 (Pubitemid 44521110)